REG - IQ-AI Limited - Update Regarding Imaging Biometrics LLC

IQ-AIAnnouncement

18/10/2023 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231018:nRSR5666Qa&default-theme=true

RNS Number : 5666Q  IQ-AI Limited  18 October 2023

IQ-AI Ltd

 

("IQ-AI" or the "Company")

 

IB Neuro Reveals the Hidden Secrets of High-Grade Glioma's Invasive Margins

 

October 18, 2023, Imaging Biometrics, LLC (IB), a wholly owned subsidiary of
IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a landmark study
published in the journal, Nature Communications. The study, Integrated
molecular and multiparametric MRI mapping of high-grade glioma identifies
regional biologic signatures
(https://www.nature.com/articles/s41467-023-41559-1) , represents the first
large-scale characterization of the invasive tumor margins of high-grade
glioma (HGG) using multi-regional genomic/transcriptomic sequencing with
spatially matched MRI measurements in glioma.

 

High-grade glioma (HGG) is a deadly brain cancer that often recurs after
surgery, due to the presence of residual tumor cells in the invasive margins
of the tumor that are often not surgically removed.  These tumor cells are
often invisible on standard imaging and may be hard to access and sample
during surgery. To address this challenge, a multi-center team, led by Leland
S. Hu, M.D., a neuroradiologist at Mayo Clinic in Arizona, has developed a
novel approach that uses non-invasive imaging to characterize the invasive
margins. Specifically, computations performed by IB Neuro's dynamic
susceptibility contrast (DSC) magnetic resonance imaging (MRI) software was
central to the study.

 

The researchers obtained multiple biopsies from different regions of each
patient's tumor and recorded the precise location of each biopsy using
stereotactic coordinates. Each biopsy sample was then matched with the
corresponding measurements derived from IB Neuro and other technologies. By
integrating genomic, transcriptomic, and MRI data, the researchers were able
to identify distinct imaging patterns that matched key genetic and molecular
features of the invasive tumor margins, which were also different from the
more central core tumor regions.

 

The investigators found that the invasive tumor margins contain biologically
distinct genetic and molecular alterations that not only underlie aggressive
behavior and disease recurrence but also give insights to potentially new
susceptibilities to treatment that could improve future outcomes.

 

"This is yet another application of IB Neuro's impact on the care of brain
cancer patients," said Trevor Brown, CEO of IQ-AI. "Our collaborators continue
to use IB Software to advance our understanding and ultimately improve
outcomes," Brown added.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKFBBNBDDAKD